In Q4 2024, billionaire investor Stanley Druckenmiller greatly expanded his holdings in Teva Pharmaceuticals by purchasing 7,569,450 shares, raising his stake by 530%. This move positions Teva as the fourth largest investment in the Duquesne Family Office portfolio. Teva, which has faced numerous challenges including litigation over the opioid crisis and a decline in stock price, is now showing signs of recovery, making many believe it holds substantial upside potential despite its troubled history.
Druckenmiller's significant investment in Teva Pharmaceuticals signals a strong belief in the firm's recovery, making it the fourth largest holding in Duquesne's portfolio.
Despite a troubled past, Teva's recent settlement over opioid litigation and the potential for growth create a compelling case for investors.
Collection
[
|
...
]